Efficacy and safety of TMC278 in treatment‐naïve, HIV‐1‐infected patients with HBV/HCV co‐infection enrolled in the phase III ECHO and THRIVE trials

M Nelson; G Amaya; N Clumeck; C Arns Da Cunha; D Jayaweera; P Junod; L Taisheng; P Tebas; M Stevens; A Buelens; S Vanveggel; K Boven

Journal ArticleOPEN ACCESS

Efficacy and safety of TMC278 in treatment‐naïve, HIV‐1‐infected patients with HBV/HCV co‐infection enrolled in the phase III ECHO and THRIVE trials

Nelson M
Amaya G
Clumeck N
et al.

Journal of the International AIDS Society (2010) 13(S4)

DOI: 10.1186/1758-2652-13-s4-p210

N/ACitations

5Readers

Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK

Cite

CITATION STYLE

APA

Nelson, M., Amaya, G., Clumeck, N., Arns Da Cunha, C., Jayaweera, D., Junod, P., … Boven, K. (2010). Efficacy and safety of TMC278 in treatment‐naïve, HIV‐1‐infected patients with HBV/HCV co‐infection enrolled in the phase III ECHO and THRIVE trials. Journal of the International AIDS Society, 13(S4). https://doi.org/10.1186/1758-2652-13-s4-p210

Efficacy and safety of TMC278 in treatment‐naïve, HIV‐1‐infected patients with HBV/HCV co‐infection enrolled in the phase III ECHO and THRIVE trials

Abstract

Cite

Register to see more suggestions